A NAD+ dosage search needs the ingredient first
There's no useful number without a name and a route. Here are two study examples, with their limits kept attached.
What did the oral studies use?
NAD+ dosage searches can mix up NAD+ itself with its precursors. A precursor is an ingredient the body uses to make NAD+. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are two examples.
In a 2019 oral NR trial, healthy overweight adult participants received 100, 300 or 1000 mg daily for eight weeks. Their blood NAD+ increased, with no significant difference in reported health problems from placebo, a dummy comparison treatment. These were study amounts for swallowed NR.
In a 2021 oral NMN study, participants were postmenopausal women with prediabetes who received 250 mg daily for ten weeks. Their muscles became more responsive to insulin, but body composition (the mix of fat and other tissue) and HbA1c didn't change. HbA1c measures blood sugar over time.
Those details describe what researchers tested. They don't select a starting amount, a target or a schedule for anyone reading this page.
Why can't those numbers become a plan?
Combining the largest amount in one paper with the longest duration in another creates a plan neither study tested. The research page looks at what those results actually mean.
The same problem comes up when an oral amount is carried across to an injection. A different ingredient or route needs its own evidence. There's no conversion here from a swallowed precursor to IV NAD+.
The study group matters too. A finding in postmenopausal women with prediabetes doesn't tell us what will happen to someone with a different health history. The participant details can be as useful as the amount. The ingredient alone doesn't capture someone's health history.
What can a prescriber help explain?
A conversation can cover the proposed preparation, the reason for considering it, other medicines and the person's health history. Useful questions include which study matches the proposal and what outcome would count as a benefit.
A review of human ageing studies found limited evidence of health benefits and gaps in measurements inside human tissues. More NAD+ in blood doesn't establish the best amount for improving health. These sources don't establish a best morning or evening schedule either.
Compounded NAD+ is not FDA-approved. FDA describes what that means for safety, effectiveness and quality review. A prescription is an individual decision, not an assurance that a research result will happen again.
The study amount belongs to the study.